Annals of Laboratory Medicine

Korean Society for Laboratory Medicine (대한진단검사의학회)
권호 표지
DOI QR코드

DOI QR Code

Abnormalities in Chromosomes 1q and 13 Independently Correlate With Factors of Poor Prognosis in Multiple Myeloma

  • Kim, Miyoung (Department of Laboratory Medicine, Hallym University College of Medicine) ;
  • Ju, Young-Su (Department of Occupational and Environmental Medicine, Hallym University College of Medicine) ;
  • Lee, Eun Jin (Department of Laboratory Medicine, Hallym University College of Medicine) ;
  • Kang, Hee Jung (Department of Laboratory Medicine, Hallym University College of Medicine) ;
  • Kim, Han-Sung (Department of Laboratory Medicine, Hallym University College of Medicine) ;
  • Cho, Hyoun Chan (Department of Laboratory Medicine, Hallym University College of Medicine) ;
  • Kim, Hyo Jung (Department of Internal Medicine, Hallym University College of Medicine) ;
  • Kim, Jung-Ah (Department of Laboratory Medicine, Seoul National University College of Medicine) ;
  • Lee, Dong Soon (Department of Laboratory Medicine, Seoul National University College of Medicine) ;
  • Lee, Young Kyung (Department of Laboratory Medicine, Hallym University College of Medicine)
  • Received : 2016.01.05
  • Accepted : 2016.06.28
  • Published : 2016.11.01
⟨ Previous Next ⟩

Abstract

Background: We comprehensively profiled cytogenetic abnormalities in multiple myeloma (MM) and analyzed the relationship between cytogenetic abnormalities of undetermined prognostic significance and established prognostic factors. Methods: The karyotype of 333 newly diagnosed MM cases was analyzed in association with established prognostic factors. Survival analysis was also performed. Results: MM with abnormal karyotypes (41.1%) exhibited high international scoring system (ISS) stage, frequent IgA type, elevated IgG or IgA levels, elevated calcium levels, elevated creatine (Cr) levels, elevated ${\beta}2-microglobulin$ levels, and decreased Hb levels. Structural abnormalities in chromosomes 1q, 4, and 13 were independently associated with elevated levels of IgG or IgA, calcium, and Cr, respectively. Chromosome 13 abnormalities were associated with poor prognosis and decreased overall survival. Conclusions: This is the first study to demonstrate that abnormalities in chromosomes 1q, 4, and 13 are associated with established factors for poor prognosis, irrespective of the presence of other concurrent chromosomal abnormalities. Chromosome 13 abnormalities have a prognostic impact on overall survival in association with elevated Cr levels. Frequent centromeric breakpoints appear to be related to MM pathogenesis.

Keywords

Acknowledgement

Supported by : Hallym University, National Research Foundation of Korea (NRF)

References

  1. Shaughnessy JD Jr, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007;109:2276-84. https://doi.org/10.1182/blood-2006-07-038430
  2. Segges P and Braggio E. Genetic markers used for risk stratification in multiple myeloma. Genet Res Int 2011;2011:798089
  3. Bergsagel PL and Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005;23:6333-8. https://doi.org/10.1200/JCO.2005.05.021
  4. Rajkumar SV. Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 2013;88:226-35.
  5. Swerdlow SH, Campo E, et al. WHO classification of tumours of hematopoietic and lymphoid tissues. Lion: IARC Press, 2008.
  6. Sawyer JR, Waldron JA, Jagannath S, Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 1995; 82:41-9. https://doi.org/10.1016/0165-4608(94)00284-I
  7. Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, Sawyer JR, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 2006; 108:1724-32. https://doi.org/10.1182/blood-2006-03-009910
  8. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009;23;2210-21. https://doi.org/10.1038/leu.2009.174
  9. Chng WJ, Santana-Davila R, Van Wier SA, Ahmann GJ, Jalal SM, Bergsagel PL, et al. Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia 2006;20: 807-13. https://doi.org/10.1038/sj.leu.2404172
  10. Avet-Louseau H, Daviet A, Sauner S, Bataille R; Intergroupe Francophone du Myelome. Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13. Br J Haematol 2000;111:1116-7. https://doi.org/10.1046/j.1365-2141.2000.02488.x
  11. Lode L, Eveillard M, Trichet V, Soussi T, Wuillème S, Richebourg S, et al. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica 2010;95:1973-6. https://doi.org/10.3324/haematol.2010.023697
  12. Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy J, Palumbo A, Durie B, et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 2011;117:4696-700. https://doi.org/10.1182/blood-2010-10-300970
  13. Marzin Y, Jamet D, Douet-Guilbert N, Morel F, Le Bris MJ, Morice P, et al. Chromosome 1 abnormalities in multiple myeloma. Anticancer Res 2006;26:953-9.
  14. Wu KL, Beverloo B, Lokhorst HM, Segeren CM, van der Holt B, Steijaert MM, et al. Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Br J Haematol 2007;136:615-23. https://doi.org/10.1111/j.1365-2141.2006.06481.x
  15. Boyd KD, Ross FM, Walker BA, Wardell CP, Tapper WJ, Chiecchio L, et al. Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. Clin Cancer Res 2011;17:7776-84. https://doi.org/10.1158/1078-0432.CCR-11-1791
  16. Walker BA, Leone PE, Chiecchio L, Dickens NJ, Jenner MW, Boyd KD, et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood 2010;116:e56-65. https://doi.org/10.1182/blood-2010-04-279596
  17. Zhan F, Colla S, Wu X, Chen B, Stewart JP, Kuehl WM, et al. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and-independent mechanisms. Blood 2007;109:4995-5001. https://doi.org/10.1182/blood-2006-07-038703
  18. Poretti G, Kwee I, Bernasconi B, Rancoita PM, Rinaldi A, Capella C, et al. Chromosome 11q23.1 is an unstable region in B-cell tumor cell lines. Leuk Res 2011;35:808-13. https://doi.org/10.1016/j.leukres.2010.10.032
  19. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998;91:3-21.
  20. Shaffer LG and Tommerup N, eds. ISCN 2005: an international system for human cytogenetic nomenclature. Basel, Switzerland: Karger Medical and Scientific Publishers, 2005.
  21. Shaffer LG, Slovak ML, et al. eds. ISCN 2009: an international system for human cytogenetic nomenclature. Basel, Switzerland: Karger Medical and Scientific Publishers, 2009.
  22. Shaffer LG, McGowan-Jordan J, et al. eds. ISCN 2013: an international system for human cytogenetic nomenclature. Basel, Switzerland: Karger Medical and Scientific Publishers, 2013.
  23. Durie BG and Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-54. https://doi.org/10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U
  24. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-20. https://doi.org/10.1200/JCO.2005.04.242
  25. Drayson M, Begum G, Basu S, Makkuni S, Dunn J, Barth N, et al. Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials. Blood 2006;108:2013-9. https://doi.org/10.1182/blood-2006-03-008953
  26. Bradwell A, Harding S, Fourrier N, Mathiot C, Attal M, Moreau P, et al. Prognostic utility of intact immunoglobulin $Ig'{\kappa}/Ig'{\lambda}$ ratios in multiple myeloma patients. Leukemia 2013;27:202-7. https://doi.org/10.1038/leu.2012.159
  27. Oh S, Koo DH, Kwon MJ, Kim K, Suh C, Min CK, et al. Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study. Ann Hematol 2014;93:1353-61. https://doi.org/10.1007/s00277-014-2057-5
  28. Cigudosa JC, Rao PH, Calasanz MJ, Odero MD, Michaeli J, Jhanwar SC, et al. Characterization of nonrandom chromosomal gains and losses in multiple myeloma by comparative genomic hybridization. Blood 1998; 91:3007-10.
  29. Kim S, Kim H, Kang H, Kim J, Eom H, Kim T, et al. Clinical significance of cytogenetic aberrations in bone marrow of patients with diffuse large B-cell lymphoma: prognostic significance and relevance to histologic involvement. J Hematol Oncol 2013;6:76. https://doi.org/10.1186/1756-8722-6-76
  30. Sawyer JR, Tricot G, Mattox S, Jagannath S, Barlogie B. Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin. Blood 1998;91:1732-41.
  31. Lauta VM. Interleukin-6 and the network of several cytokines in multiple myeloma: an overview of clinical and experimental data. Cytokine 2001; 16:79-86. https://doi.org/10.1006/cyto.2001.0982
  32. Lamant L, Dastugue N, Pulford K, Delsol G, Mariame B. A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. Blood 1999;93:3088-95.
  33. Felix RS, Colleoni GW, Caballero OL, Yamamoto M, Almeida MS, Andrade VC, et al. SAGE analysis highlights the importance of p53csv, ddx5, mapkapk2 and ranbp2 to multiple myeloma tumorigenesis. Cancer Lett 2009;278:41-8. https://doi.org/10.1016/j.canlet.2008.12.022
  34. Nahi H, Sutlu T, Jansson M, Alici E, Gahrton G. Clinical impact of chromosomal aberrations in multiple myeloma. J Intern Med 2011;269:137-47. https://doi.org/10.1111/j.1365-2796.2010.02324.x
  35. Smadja NV, Fruchart C, Isnard F, Louvet C, Dutel JL, Cheron N, et al. Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia 1998;12:960-9. https://doi.org/10.1038/sj.leu.2401041

Cited by

  1. IgA Type Multiple Myeloma, Clinical Features, and Prognosis vol.131, pp.10, 2016, https://doi.org/10.4103/0366-6999.231513
  2. Prognostic value of integrated cytogenetic, somatic variation, and copy number variation analyses in Korean patients with newly diagnosed multiple myeloma vol.16, pp.2, 2016, https://doi.org/10.1371/journal.pone.0246322